Malignant Tumor
Conditions
Brief summary
Tumor-specific antigens can be induced by demethylation drugs. Antigen-targeting DC-CTL cells supposed to eliminate cancer cells efficiently and specifically. In this study investigators co-culture DCs cells with peptides derived from tumor specific antigen to generate antigen-specific DC-CTLs (Ag-CTL). Following treatment with demethylation drugs, Ag-CTL will be used to eliminate tumor cells. This study aims to evaluate the effectiveness and safety of Ag-CTL combined with demethylation drugs.
Detailed description
A large number of studies have confirmed that demethylated drug decitabine can effectively induce tumor-specific antigen expression. Tumor-specific antigens have strong specificity and are ideal therapeutic targets. In this study, tumor-specific antigens were used as therapeutic targets. The researchers screened the tumor-specific epitope peptides through bioinformatics database combined with in vitro experiments. The peptide-loaded DCs are co-cultured with T lymphocytes to induce the proliferation of CTLs, which are then refusion to tumor patients to treating diseases.
Interventions
BIOLOGICALDC-CTL
DAC combined with Ag-CTL
Sponsors
Shenzhen University General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female patients aged 18-70 (including 18 and 70 years old); 2. Diagnosed as malignant tumor by pathological and histological examination; 3. Patients with ECOG score \<2 and estimated survival time\>3 months; 4. Patients need to receive systemic combined chemotherapy according to their condition; other treatments such as surgery, radiotherapy, and targeted therapy are excluded; 5. The previous treatment-related toxicity of the patient 2 weeks before the enrollment had returned to \<1 grade at the time of enrollment (except for low-grade toxicity such as alopecia and peripheral neuritis); 6. The patient's intravenous access is unobstructed, which can meet the needs of intravenous drip; 7. The patient voluntarily participates and signs the informed consent form, and follows the research treatment plan and visit plan;
Exclusion criteria
* Any one of the
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | From date of initial treatment until the date of first documented progression, assessed up to 36 months. | progression free survival time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | From date of diagnosis until the end of the follow-up, assessed up to 36 months. | over all survival time |
Countries
China
Contacts
Primary ContactShujiao He, Dr
Outcome results
None listed